Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CD-19 82 CR Leu13 PI3 K PI 3K NF?B
- Product Overview:
CD19 is a type I transmembrane protein and member of the immunoglobulin superfamily that functions as a B cell receptor (BCR) co-receptor.{57380,57381} It is composed of an extracellular N-terminal domain containing two C2-type immunoglobulin-like (Ig-like) domains and several glycosylation sites, a transmembrane domain, and a C-terminal cytoplasmic domain containing nine tyrosine residues, which are subject to phosphorylation and mediate intracellular signaling. It is expressed on the surface of, and used as a marker for, B cells, and its expression increases during B cell maturation but decreases upon plasma cell differentiation.{57380,57381,57382} CD19 has important roles in B cell proliferation, differentiation, and survival.{57380} It associates with CD21, also known as complement receptor 2 (CR2), as well as CD82 and Leu-13, forming a multimeric complex that enhances BCR signaling.{57380,57381} CD19 functions as an adaptor protein, recruiting various cytoplasmic signaling proteins to the cell membrane that activate numerous intracellular signaling pathways, including PI3K, MAPK, and NF-?B.{57380,57381,57383} CD19 protein levels are increased in tumor cells isolated from patients with a variety of cancers of B cell origin, including chronic myelocytic leukemia and B cell lymphomas, and decreased in B cells isolated from patients with systemic lupus erythematosus (SLE).{57384,57385,57382,57381,57380} Cayman’s CD19 (C-Term) Rabbit Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.